文献速递心脑血管急症

血管造影定量血流比指导的冠状动脉介入治疗(FAVOR III China):一项多中心、随机、假手术对照试验

Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
PubMed 文献 · Lancet · 2021-11-04
一句话结论在计划接受PCI的患者中,与标准造影指导相比,QFR指导的病变选择策略减少了1年主要不良心脏事件(5.8% vs 8.8%,HR 0.65)。

FAVOR III China是在中国26家医院开展的多中心、盲法、随机、假手术对照试验,纳入3847例年龄≥18岁、有不稳定型心绞痛或心肌梗死至少72小时且至少一处直径狭窄50-90%的冠心病患者。患者随机接受QFR指导策略(仅当QFR≤0.80时行PCI)或造影指导策略(基于标准视觉造影评估行PCI)。主要终点为1年主要不良心脏事件(全因死亡、心肌梗死或缺血驱动的血运重建的复合终点)。结果显示QFR指导组主要终点发生率为5.8%,造影指导组为8.8%(差异-3.0%,95%CI -4.7至-1.4;HR 0.65,95%CI 0.51至0.83;p=0.0004),主要由心肌梗死和缺血驱动的血运重建减少所驱动。

要点

  • QFR指导组1年主要不良心脏事件发生率为5.8%,造影指导组为8.8%,差异-3.0%(95%CI -4.7至-1.4),HR 0.65(95%CI 0.51至0.83),p=0.0004。
  • 获益主要由心肌梗死和缺血驱动的血运重建减少所驱动。
  • QFR指导策略为仅当QFR≤0.80时行PCI。
  • 研究纳入直径狭窄50-90%、参考血管直径至少2.5 mm(视觉评估)的患者。

适用人群与场景

  • 年龄18岁及以上,有不稳定型心绞痛或心肌梗死至少72小时前发生,且至少一处冠状动脉病变直径狭窄50-90%、参考血管直径至少2.5 mm(视觉评估)的患者。
  • 排除标准:选择不接受PCI或由医生撤回的患者(共22例)。

诊断标准与关键阈值

  • QFR指导策略:仅当QFR≤0.80时行PCI。
  • 造影指导策略:基于标准视觉造影评估行PCI。

处置流程与药物剂量

  • QFR指导组:仅当QFR≤0.80时行PCI。
  • 造影指导组:基于标准视觉造影评估行PCI。

研究设计与关键结果

  • 研究类型:多中心、盲法、随机、假手术对照试验,在中国26家医院开展。
  • 样本量:3847例患者入组,排除22例后,意向性治疗人群为3825例(QFR指导组1913例,造影指导组1912例)。
  • 人群特征:平均年龄62.7岁(SD 10.1),男性2699例(70.6%),女性1126例(29.4%),糖尿病1295例(33.9%),急性冠脉综合征2428例(63.5%)。
  • 主要终点:1年主要不良心脏事件(全因死亡、心肌梗死或缺血驱动的血运重建的复合终点)在QFR指导组发生110例(Kaplan-Meier估计率5.8%),造影指导组发生167例(8.8%),差异-3.0%(95%CI -4.7至-1.4),HR 0.65(95%CI 0.51至0.83),p=0.0004。
  • 获益主要由心肌梗死和缺血驱动的血运重建减少所驱动。

证据类型、等级与局限

  • 证据类型:多中心、盲法、随机、假手术对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于计划接受PCI的冠心病患者,QFR指导的病变选择策略较标准造影指导改善了1年临床结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Compared with visual angiographic assessment, pressure wire-based physiological measurement more accurately identifies flow-limiting lesions in patients with coronary artery disease. Nonetheless, angiography remains the most widely used method to guide percutaneous coronary intervention (PCI). In FAVOR III China, we aimed to establish whether clinical outcomes might be improved by lesion selection for PCI using the quantitative flow ratio (QFR), a novel angiography-based approach to estimate the fractional flow reserve.

METHODS: FAVOR III China is a multicentre, blinded, randomised, sham-controlled trial done at 26 hospitals in China. Patients aged 18 years or older, with stable or unstable angina pectoris or patients who had a myocardial infarction at least 72 h before screening, who had at least one lesion with a diameter stenosis of 50-90% in a coronary artery with a reference vessel of at least 2·5 mm diameter by visual assessment were eligible. Patients were randomly assigned to a QFR-guided strategy (PCI performed only if QFR ≤0·80) or an angiography-guided strategy (PCI based on standard visual angiographic assessment). Participants and clinical assessors were masked to treatment allocation. The primary endpoint was the 1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia-driven revascularisation. The primary analysis was done in the intention-to-treat population. The trial was registered with ClinicalTrials.gov (NCT03656848).

FINDINGS: Between Dec 25, 2018, and Jan 19, 2020, 3847 patients were enrolled. After exclusion of 22 patients who elected not to undergo PCI or who were withdrawn by their physicians, 3825 participants were included in the intention-to-treat population (1913 in the QFR-guided group and 1912 in the angiography-guided group). The mean age was 62·7 years (SD 10·1), 2699 (70·6%) were men and 1126 (29·4%) were women, 1295 (33·9%) had diabetes, and 2428 (63·5%) presented with an acute coronary syndrome. The 1-year primary endpoint occurred in 110 (Kaplan-Meier estimated rate 5·8%) participants in the QFR-guided group and in 167 (8·8%) participants in the angiography-guided group (difference, -3·0% [95% CI -4·7 to -1·4]; hazard ratio 0·65 [95% CI 0·51 to 0·83]; p=0·0004), driven by fewer myocardial infarctions and ischaemia-driven revascularisations in the QFR-guided group than in the angiography-guided group.

INTERPRETATION: In FAVOR III China, among patients undergoing PCI, a QFR-guided strategy of lesion selection improved 1-year clinical outcomes compared with standard angiography guidance.

FUNDING: Beijing Municipal Science and Technology Commission, Chinese Academy of Medical Sciences, and the National Clinical Research Centre for Cardiovascular Diseases, Fuwai Hospital.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Xu B, Tu S, Song L, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet. 2021. PMID: 34742368. doi:10.1016/S0140-6736(21)02248-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。